Barclays’s Celularity CELU Stock Holding History

Barclays’s Portfolio CELU Stock Details CELU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-3,234	Closed	-$20K	–	4606
2023 Q1	$20K	Buy	3,234 +1,529	+90%	+$12.3K	﹤0.01%	4658
2022 Q4	$22K	Buy	1,705 +1,419	+496%	+$26.2K	﹤0.01%	4785
2022 Q3	$7K	Buy	286 +208	+267%	+$6.31K	﹤0.01%	4414
2022 Q2	$3K	Buy	+78	New	+$6.34K	﹤0.01%	4839

Other funds holding CELU

SIC

Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return

CVSC

C.V. Starr & Co New York $187M AUM 26.03% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BFO

Biltmore Family Office Charlotte, North Carolina $761M AUM 31.91% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Barclays's CELU Position: Q2 2023 in Review

Barclays sold out of Celularity (CELU) in Q2 2023, closing a stake of 3,234 shares — an estimated $20K sold.

Barclays first reported a position in CELU in Q2 2022 and held it in 4 quarters. The position peaked at $22K in Q4 2022. 56 funds tracked by Wall St. Rank hold CELU as of Q2 2023.

Barclays reported no remaining Celularity position as of Q2 2023 after selling out during the quarter.
Barclays sold 3,234 Celularity shares in Q2 2023, an estimated $20K.
Barclays first reported a position in Celularity in Q2 2022 and held it in 4 quarters.
Barclays's Celularity position peaked at $22K in Q4 2022.
56 funds tracked by Wall St. Rank held Celularity as of Q2 2023.

Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.